• If you are wondering whether Terumo's current share price gives you value or leaves you paying too much, this article walks through what the numbers are really saying about the stock.
• Terumo's shares last closed at ¥2,088, with returns of 2.2% over 7 days and 3.9% over 30 days, but a 7.7% decline year to date and a 23.8% decline over the past year. This is set against gains of 22.2% over 3 years and 13.7% over 5 years.
• Recent coverage has focused on Terumo's share price performance and how investors are reassessing the company after the 1 year decline, alongside the longer term 3 and 5 year gains. This mix of short term weakness and longer term gains is keeping attention on whether the current price reflects the business fundamentals.
• On Simply Wall St's valuation checks, Terumo scores 4 out of 6, which raises the question of how different methods like DCF, multiples and peer comparisons line up, and whether there is an even more useful way to think about valuation that will be covered at the end of this article.

Find out why Terumo's -23.8% return over the last year is lagging behind its peers.

Approach 1: Terumo Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and discounting them back to the present. It is essentially asking what Terumo's future cash generation is worth in today's yen.

For Terumo, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows in ¥. The latest twelve month Free Cash Flow is ¥119,784.7m. Analysts provide detailed Free Cash Flow estimates out to 2030, with Simply Wall St extending those projections further using its own assumptions. By 2035, the model uses a projected Free Cash Flow of ¥261,220.4m, with intermediate years stepping up between those two points.

When all those projected cash flows are discounted back, the DCF output suggests an intrinsic value of about ¥2,802.72 per share. Compared with the recent share price of ¥2,088, this implies Terumo trades at roughly a 25.5% discount to that estimate, which indicates that the shares appear undervalued on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Terumo is undervalued by 25.5%. Track this in your watchlist or portfolio, or discover 23 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Terumo.

Approach 2: Terumo Price vs Earnings

For a profitable company like Terumo, the P/E ratio is a practical way to think about valuation because it links what you pay for each share to the earnings that each share currently generates. Investors generally accept that higher expected earnings growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually call for a lower, more cautious multiple.

Terumo currently trades on a P/E of 24.1x. That sits above the Medical Equipment industry average of 15.3x and also above the peer average of 17.7x, so on simple comparisons the shares price in a higher multiple than many sector peers.

Simply Wall St’s Fair Ratio for Terumo is 31.3x. This is a proprietary estimate of what P/E might be reasonable given factors such as Terumo’s earnings growth profile, profitability, industry, market capitalization and company specific risks. Because it adjusts for these factors rather than relying on broad peer or industry groupings, it can give a more tailored reference point for each company. Compared with this Fair Ratio, Terumo’s current 24.1x P/E is lower, which suggests the shares screen as undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 10 top founder-led companies.

Upgrade Your Decision Making: Choose your Terumo Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St's Community page let you turn your view of Terumo into a clear story that connects assumptions about future revenue, earnings and margins to a Fair Value, then compares that Fair Value with the current share price to help decide whether the stock looks attractive or expensive for you.

Each Narrative effectively links the story you believe, such as a more optimistic case where Terumo reaches earnings of ¥198.9b by around 2028 on a 33.4x P/E, or a more cautious case where earnings are closer to ¥156.8b on a 27.7x P/E, to a financial forecast and price target range between ¥2,550 and ¥3,900. The platform keeps these views updated when fresh information like news or earnings is added so you can quickly see how your Terumo Narrative stacks up against what other investors think.

Do you think there's more to the story for Terumo? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.